Drugs
ASBL develops drugs to benchmark performance of ASBL machines in drug development
Mohsina (metabolic)
MID (metabolic)
NF-01 (metabolic)
Stage: Preclinical
Indication: Insulin-resistant type 2 diabetes
Class: LNP-mRNA and antisense oligonucleotide combination
Mechanism of action: Targets metabolic dysreglation in liver and muscle. Insulin replacement to recover normal metabolic function.
Precision medicine: Mohsina and MID combination drug precisely recovers metabolism affected by diabetes. Mohsina:MID drug ratio in combination drug is personalized for patients.
Stage: Discovery
Indication: Insulin-deficient type 2 diabetes
Class: Autologous cell therapy
Mechanism of action: Cell therapy to recover pancreatic function of endogenous insulin production
Precision medicine: MID and Mohsina combination drug precisely recovers metabolism affected by diabetes. Mohsina:MID drug ratio in combination drug is personalized for patients.
Stage: Discovery
Indication: Metabolic dysfunction-associated steatotic liver disease (MASLD) or fatty liver disease
Class: Small molecule
Mechanism of action: Liver-targeted small molecule delivery reduces liver inflammation